The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ADVM | -49.63% | -96.71% | -49.44% | -98% |
| S&P | +16.9% | +95.99% | +14.39% | +253% |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Investors are running for the hills following the company's latest clinical update.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.54M | 44.0% |
| Gross Margin | 11.00% | 0.0% |
| Market Cap | $44.92M | -68.5% |
| Market Cap / Employee | $0.29M | 0.0% |
| Employees | 155 | 28.1% |
| Net Income | -$49.19M | -166.2% |
| EBITDA | -$49.32M | -75.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.42M | -66.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $84.86M | 34.0% |
| Short Term Debt | $7.36M | -30.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -93.88% | -53.5% |
| Return On Invested Capital | -58.01% | -12.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$38.89M | -95.8% |
| Operating Free Cash Flow | -$38.77M | -95.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.87 | 0.67 | 0.63 | 1.70 | 117.63% |
| Price to Sales | 146.55 | 97.59 | 91.50 | 45.17 | 113.43% |
| Price to Tangible Book Value | 0.87 | 0.67 | 0.63 | 1.70 | 117.63% |
| Enterprise Value to EBITDA | -2.23 | -1.42 | -2.14 | -1.89 | 23.03% |
| Return on Equity | -76.3% | -144.4% | -128.0% | -222.3% | 232.97% |
| Total Debt | $73.26M | $91.71M | $93.18M | $92.22M | 24.81% |
ADVM earnings call for the period ending December 31, 2020.
ADVM earnings call for the period ending June 30, 2020.
ADVM earnings call for the period ending March 31, 2020.
ADVM earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
